Last reviewed · How we verify

Pfenex, Inc — Portfolio Competitive Intelligence Brief

Pfenex, Inc pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Teriparatide (PF708) Teriparatide (PF708) phase 3 Parathyroid hormone analog PTH1R Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bio Sidus SA · 1 shared drug class
  2. M.D. Anderson Cancer Center · 1 shared drug class
  3. Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 shared drug class
  4. University of Edinburgh · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pfenex, Inc:

Cite this brief

Drug Landscape (2026). Pfenex, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pfenex-inc. Accessed 2026-05-14.

Related